DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4.
Sign Up to like & getrecommendations! Published in 2018 at "Molecular cell"
DOI: 10.1016/j.molcel.2018.06.036
Abstract: The bromodomain and extra-terminal domain (BET) protein BRD4 is emerging as a promising anticancer therapeutic target. However, resistance to BET inhibitors often occurs, and it has been linked to aberrant degradation of BRD4 protein in… read more here.
Keywords: cancer; dub3; inhibitor resistance; bet inhibitor ... See more keywords